Exhibit 99.1 DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results Conference Call and Webcast May 9 at 8:00 AM Eastern Time / 7:00 AM Central Time ● First Patient Dosed in Relaunch of ReMEDy2 Stroke Trial ● Clinical Operations Team Expanded to Support Global Expansion ● $46.5 Million Cash with Runway to 2026 Minneapolis, Minnesota – May 8, 2024 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on d ...